How Does Mounjaro Work?

The Dual-Receptor Mechanism: Why Mounjaro Is Different

Mounjaro works by binding to and activating two incretin hormone receptors at once. Most GLP-1 drugs target only the GLP-1 receptor. Tirzepatide adds a second target, the GIP receptor, and that addition changes the pharmacological profile substantially. The result is a drug with appetite-suppressing, insulin-amplifying, and glucagon-suppressing effects that appear to exceed what either receptor agonist achieves alone.

What GLP-1 Receptors Do

GLP-1 is released from intestinal L-cells after eating. When tirzepatide activates GLP-1 receptors in the pancreas, it stimulates insulin secretion in a glucose-dependent manner, meaning the drug amplifies insulin release only when blood glucose is already elevated. This glucose-dependency is medically important: it substantially limits the hypoglycemia risk that older insulin secretagogues carry. GLP-1 receptor activation also suppresses glucagon, slows gastric emptying, and signals satiety centers in the hypothalamus and brainstem. The FDA approved the first GLP-1 receptor agonist, exenatide (Byetta), in 2005, and the class has expanded steadily since [1].

What GIP Receptors Add

GIP is released from intestinal K-cells and historically received less clinical attention than GLP-1. Research published in Cell Metabolism showed that GIP receptor activation enhances insulin secretion synergistically with GLP-1 signaling and may also act directly on adipose tissue to modulate lipid storage [2]. Tirzepatide's GIP agonism appears to reduce GLP-1-related nausea, which may partly explain why tirzepatide tolerability profiles compare favorably to some single-receptor GLP-1 agents. The precise relative contribution of GIP versus GLP-1 agonism to tirzepatide's clinical effects remains an area of active investigation.

How the Two Pathways Interact

Tirzepatide was engineered as a single peptide molecule that carries activity at both receptors. A 2022 New England Journal of Medicine paper describing the SURPASS-2 trial noted that the molecule's structure allows it to bind GIP receptors with roughly equivalent potency to native GIP while retaining high-affinity GLP-1 receptor binding [3]. The interaction between the two activated pathways produces insulin secretion that is greater than additive compared to either pathway alone in preclinical models, according to data published in Science Translational Medicine [4].

Blood Sugar Control: What the SURPASS Trials Showed

The SURPASS clinical program enrolled patients with type 2 diabetes across five major randomized controlled trials. These trials provide the primary evidence base for tirzepatide's glycemic effects.

SURPASS-1: Tirzepatide Alone

SURPASS-1 (N=478) tested tirzepatide monotherapy against placebo in patients with type 2 diabetes inadequately controlled on diet and exercise alone. At 40 weeks, tirzepatide 15 mg reduced HbA1c by a mean of 2.07 percentage points, with 92% of participants reaching HbA1c <7.0% compared to 20% on placebo [5]. Body weight fell by a mean of 9.5 kg in the 15 mg group.

SURPASS-2: Head-to-Head Against Semaglutide

SURPASS-2 is the trial most directly relevant to patients choosing between Mounjaro and Ozempic. In this 1,879-participant, 40-week trial, tirzepatide 15 mg reduced HbA1c by 2.01% versus 1.86% for semaglutide 1 mg (P<0.001) [3]. Weight loss was 11.2 kg with tirzepatide 15 mg versus 5.3 kg with semaglutide 1 mg. The tirzepatide 10 mg dose also outperformed semaglutide 1 mg on both endpoints.

SURPASS-3, 4, and 5

SURPASS-3 compared tirzepatide to titrated insulin degludec; SURPASS-4 studied tirzepatide in patients at high cardiovascular risk who were already on basal insulin; and SURPASS-5 added tirzepatide to insulin glargine. Across these trials, tirzepatide consistently produced HbA1c reductions of 1.7% to 2.4% and weight loss of 6 to 12 kg depending on background therapy and dose [6]. The FDA reviewed this data package before granting approval in May 2022.

Weight Loss: The SURMOUNT Program

The FDA approved tirzepatide specifically for chronic weight management under the brand name Zepbound in November 2023, based on the SURMOUNT trial program. These trials enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, but without type 2 diabetes in the primary analysis.

SURMOUNT-1 Results

SURMOUNT-1 (N=2,539) is the landmark weight-loss trial. Participants received tirzepatide 5 mg, 10 mg, or 15 mg once weekly or placebo for 72 weeks, all alongside lifestyle intervention. Mean body weight reduction was 15.0% with 5 mg, 19.5% with 10 mg, and 20.9% with 15 mg, versus 3.1% with placebo (all P<0.001) [7]. At the 15 mg dose, 57.8% of participants achieved ≥20% body weight loss. No single-agent obesity medication had previously demonstrated that proportion of patients reaching 20% weight reduction in a phase 3 trial.

SURMOUNT-2 and Cardiovascular Data

SURMOUNT-2 specifically enrolled patients with type 2 diabetes and obesity. Tirzepatide 15 mg produced 15.7% body weight reduction at 72 weeks in this population [8]. Cardiovascular outcome data from the SURMOUNT-MMO trial were still maturing at the time of this article's review; however, the FDA label notes that cardiovascular benefit has not yet been established for the weight-management indication in the way it has been for semaglutide through the STEP-HFpEF and SELECT trials.

Dosing and Titration: The Standard Protocol

Tirzepatide follows a structured dose-escalation schedule designed to minimize gastrointestinal side effects. The FDA-approved starting dose is 2.5 mg once weekly for the first four weeks. After that, the dose increases by 2.5 mg every four weeks until the patient reaches their target maintenance dose or the maximum approved dose of 15 mg weekly [9].

Injection Technique

Tirzepatide is injected subcutaneously into the abdomen, thigh, or upper arm. Patients rotate injection sites. The drug comes in prefilled single-dose pens, available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths. Each pen delivers one dose. Pens should be stored in the refrigerator between 36°F and 46°F (2°C to 8°C) and can be kept at room temperature for up to 21 days before use, according to the FDA prescribing information [9].

Dose Adjustments for Tolerability

If a patient experiences intolerable gastrointestinal side effects at any dose level, the prescribing physician may delay the scheduled increase by four weeks. The goal is the highest dose the patient tolerates, not necessarily the maximum dose. Clinical practice guidelines from the American Association of Clinical Endocrinology emphasize individualized titration rather than fixed escalation targets when patient comfort is a concern [10].

Side Effects and Safety Profile

Gastrointestinal symptoms are the most common reason patients reduce dose or discontinue tirzepatide. In SURMOUNT-1, nausea occurred in 31.0% of the 15 mg group versus 6.2% with placebo; diarrhea occurred in 22.6% versus 7.4%; and vomiting in 12.7% versus 2.3% [7]. Most of these symptoms were mild to moderate and occurred during dose escalation. They typically resolved with time or dose reduction.

Serious but Rare Risks

The FDA label carries a boxed warning for thyroid C-cell tumors based on rodent studies showing dose-dependent thyroid tumors with GLP-1 receptor agonists [9]. The human relevance of this finding is not established. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Acute pancreatitis has been reported; patients should stop the medication and seek evaluation if they develop severe, persistent abdominal pain.

Hypoglycemia Risk

Because tirzepatide's insulin-stimulating effects are glucose-dependent, hypoglycemia risk is low when tirzepatide is used as monotherapy. In SURPASS-1, severe hypoglycemia occurred in 0% of tirzepatide participants [5]. The risk increases meaningfully when tirzepatide is combined with insulin or sulfonylureas; dose reductions of those agents are often necessary at initiation.

Gallbladder Disease

Rapid weight loss with any method increases gallstone risk. In SURMOUNT-1, cholelithiasis occurred in 1.5% of the 15 mg group versus 0.2% with placebo [7]. Patients with known gallbladder disease should discuss this risk with their physician before starting.

Mounjaro vs. Ozempic: A Direct Comparison

Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg) is the most widely prescribed GLP-1 receptor agonist for type 2 diabetes. Both drugs are once-weekly injections. Tirzepatide's additional GIP mechanism accounts for most of the observed outcome differences between them.

Glycemic Control

In SURPASS-2, tirzepatide 15 mg produced an HbA1c reduction of 2.01% versus 1.86% for semaglutide 1 mg at 40 weeks [3]. The difference is statistically significant but clinically modest at these doses. Semaglutide 2 mg has not been directly compared to tirzepatide in a head-to-head RCT.

Weight Reduction

The weight loss difference is more substantial. SURPASS-2 showed 11.2 kg loss with tirzepatide 15 mg versus 5.3 kg with semaglutide 1 mg [3]. STEP-1 (N=1,961) showed semaglutide 2.4 mg (the Wegovy dose) produced 14.9% mean weight loss at 68 weeks [11], which compares to 20.9% with tirzepatide 15 mg in SURMOUNT-1, though cross-trial comparisons carry important caveats about different populations, trial designs, and background interventions.

Cardiovascular Evidence

Semaglutide has established cardiovascular outcome trial data. The LEADER trial demonstrated that liraglutide reduced major adverse cardiovascular events (MACE) in high-risk type 2 diabetes patients [12]. Semaglutide's SELECT trial (N=17,604) showed a 20% reduction in MACE with semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease, published in NEJM in 2023 [13]. Tirzepatide does not yet have published cardiovascular outcome trial results, though SURMOUNT-MMO is underway.

Who Is a Good Candidate for Mounjaro?

Tirzepatide is FDA-approved for two distinct indications requiring different documentation for prescribing and insurance coverage.

Type 2 Diabetes

Adults with type 2 diabetes who need additional glycemic control beyond diet, exercise, and/or metformin are appropriate candidates. The American Diabetes Association 2024 Standards of Care recommend GLP-1 receptor agonists and dual GIP/GLP-1 agonists as preferred add-on agents for patients with overweight, obesity, or high cardiovascular risk [14].

Obesity or Overweight with Comorbidities (Zepbound Indication)

For the weight-management indication (Zepbound), the FDA approved tirzepatide for adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease [9]. Patients without type 2 diabetes who meet these BMI criteria and cannot access Zepbound may sometimes be prescribed Mounjaro off-label for weight management, though coverage varies by insurer.

Contraindications to Screen For

Beyond the thyroid cancer contraindication, prescribers screen for a personal or family history of MEN2, active or recent pancreatitis, severe gastroparesis (since slowed gastric emptying can worsen the condition), and pregnancy. Tirzepatide should be stopped at least two months before a planned pregnancy because animal studies showed fetal harm, per the FDA prescribing information [9].

How Mounjaro Works in a Telehealth Context

Telehealth prescribing of tirzepatide follows the same clinical standards as in-person prescribing. A physician or advanced practice provider must conduct a medical history review, assess contraindications, and establish a diagnosis of type 2 diabetes or obesity before prescribing. Ongoing monitoring typically includes periodic HbA1c or fasting glucose checks, body weight tracking, and assessment of side effects at each follow-up visit.

The Endocrine Society's clinical practice guidelines on obesity pharmacotherapy specify that medications should be used as adjuncts to lifestyle intervention, not substitutes for it [15]. Patients who stop tirzepatide typically regain a substantial proportion of lost weight; SURMOUNT-4 showed that participants who discontinued tirzepatide after 36 weeks of treatment regained about two-thirds of their lost weight by week 88, while those who continued lost an additional 5.5% [16].